- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Perjeta (pertuzumab) / Roche, Tecentriq (atezolizumab) / Roche
[VIRTUAL] Checkpoint inhibition in patients with TNBC: How robust is the data today? (Singapore) - Sep 3, 2020 - Abstract #DGHO2020DGHO_516; The addition of immune checkpoint inhibitors to cytotoxic chemotherapy has also been evaluated in phase III trials with atezolizumab and pembrolizumab for patients with advanced TNBC...Patients with advanced TNBC and expression of PD-L1 in tumor-infiltrating immune cells or in both immune and cancer cells (in particular with “combined positive score” > 10%) experience a prolonged progression-free survival with atezolizumab (IMpassion 130) or pertuzumab (KEYNOTE-355)...The promise of a longer survival and a better quality of life remains to be fulfilled. The presentation and conclusions will be updated with trial results as they appear in print or at major scientific meetings.
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Clinical, P2 data, Journal, Combination therapy, Pan Tumor: A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial). (Pubmed Central) - Aug 22, 2020 Instead of focusing on 1 organ type, our trial design uses a basket study focusing on HER2 amplification, regardless of the site or origin of the cancer. The results of our study will advance clinical and scientific knowledge concerning the treatment of locally advanced, rare solid cancers harboring HER2 amplification, using the combination of trastuzumab and pertuzumab.
- |||||||||| Herceptin (trastuzumab) / Roche
Preclinical, Journal: Acquired resistance to HER2-targeted therapies creates vulnerability to ATP synthase inhibition. (Pubmed Central) - Aug 18, 2020 Furthermore, combining ATP synthase inhibitor oligomycin A with trastuzumab led to regression of trastuzumab-resistant tumors in vivo. In conclusion, we identify a novel vulnerability of cells with acquired resistance to HER2-targeted antibody therapies and reveal a new therapeutic strategy to overcome resistance.
- |||||||||| Herceptin (trastuzumab) / Roche
Journal: Semi-rational Design of Target-binding Small Proteins for Cancer Treatment (Pubmed Central) - Aug 18, 2020 Finally, four out of the 65 showed specific binding to HER2 with a dissociation constant (K) of 24-65 nM, and these were used for the detection of HER2-expressing cancer cells. Our design strategy will promote the development of antibody mimetics for the effective treatment of cancers and other diseases.
- |||||||||| doxorubicin hydrochloride / Generic mfg.
Journal: Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity. (Pubmed Central) - Aug 14, 2020 This article discusses various mechanisms that have been proposed for the cardiotoxic effects of trastuzumab and the potential risk factors that can lead to cardiotoxicity. The recently approved anti-HER2 monoclonal antibodies including pertuzumab and ado-trastuzumab (T-DM1) are also discussed.
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche
[VIRTUAL] The survival outcomes for the subsequent therapy after treatment with trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer patients (e-poster) - Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_657; Thirteen (43.3%) patients were administered a regimen containing Tmab and/or lapatinib for the first subsequent line after T-DM1...Univariate analysis showed that brain metastases(P<0.004), prior use of Pmab(P=0.03) and the PFS of T-DM1(P=0.03) were significant predictive factors for the PFS of the first subsequent therapy in HER2 positive MBC patients. Conclusions This is the first report to evaluate the survival outcomes for the post-T-DM1 therapy in Japanese HER2-positive MBC patients.Our study showed brain metastases, prior use of Pmab, and PFS of T-DM1 treatment were significantly associated with the PFS of the subsequent treatment after T-DM1 for patients with HER2-positive MBC.
- |||||||||| Herceptin (trastuzumab) / Roche
[VIRTUAL] Axillary management in patients with breast cancer and positive axilla at diagnosis (e-poster) - Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_598; With a 40% of complete axillary response rate to chemotherapy, sentinel node biopsy provides valid and reliable information about cancer stadification and could prevent lymphadenectomy, replacing it with radiotherapy and thus decreasing morbidity. the pathological response to systemic treatment has emerged as the most important predictive factor of disease-free survival on breast cancer.
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche
[VIRTUAL] The survival outcomes for the subsequent therapy after treatment with trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer patients (e-poster) - Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_337; Thirteen (43.3%) patients were administered a regimen containing Tmab and/or lapatinib for the first subsequent line after T-DM1...Univariate analysis showed that brain metastases(P<0.004), prior use of Pmab(P=0.03) and the PFS of T-DM1(P=0.03) were significant predictive factors for the PFS of the first subsequent therapy in HER2 positive MBC patients. Conclusions This is the first report to evaluate the survival outcomes for the post-T-DM1 therapy in Japanese HER2-positive MBC patients.Our study showed brain metastases, prior use of Pmab, and PFS of T-DM1 treatment were significantly associated with the PFS of the subsequent treatment after T-DM1 for patients with HER2-positive MBC.
- |||||||||| Herceptin (trastuzumab) / Roche
[VIRTUAL] Axillary management in patients with breast cancer and positive axilla at diagnosis (e-poster) - Aug 14, 2020 - Abstract #EBCCI2020EBCC-I_270; With a 40% of complete axillary response rate to chemotherapy, sentinel node biopsy provides valid and reliable information about cancer stadification and could prevent lymphadenectomy, replacing it with radiotherapy and thus decreasing morbidity. the pathological response to systemic treatment has emerged as the most important predictive factor of disease-free survival on breast cancer.
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date, Metastases: Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy (clinicaltrials.gov) - Aug 14, 2020 P2, N=45, Active, not recruiting, the pathological response to systemic treatment has emerged as the most important predictive factor of disease-free survival on breast cancer. Trial completion date: Sep 2020 --> Sep 2021 | Trial primary completion date: Sep 2020 --> Sep 2021
- |||||||||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Combination therapy, Metastases: PERNETTA: Trastuzumab & Pertuzumab Followed by T-DM1 in MBC (clinicaltrials.gov) - Aug 9, 2020 P2, N=208, Active, not recruiting, Active, not recruiting --> Completed Trial completion date: Jun 2020 --> Dec 2020
- |||||||||| Margenza (margetuximab) / MacroGenics, ZAI Lab, Perjeta (pertuzumab) / Roche
Enrollment open: MARGetuximab Or Trastuzumab (MARGOT) (clinicaltrials.gov) - Aug 7, 2020 P2, N=171, Recruiting, PAM50 intrinsic subtyping further refines our ability to identify a subset of patients for whom chemotherapy might be spared. Not yet recruiting --> Recruiting
- |||||||||| Review, Journal: Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. (Pubmed Central) - Aug 2, 2020
Parallel to this, development of ADCs in breast cancer has suffered other setbacks, including the recent failure of other agents (MM-302) as well as the suspension of a few programs (XMT-1522, ADCT-502) with the overall effect of dampening the impetus of this concept and halting/delaying the progress of drugs associated with it, particularly when immunotherapy is at the center of so many efforts...Finally, breakthroughs are occurring in the orphan triple-negative breast cancer subtype with agents targeting surface proteins. The recent results of Sacituzumab govitecan suggest substantial activity in heavily pre-treated patients and underscore the enduring relevance of antibody drug conjugates as a path towards better outcomes.
- |||||||||| Herceptin (trastuzumab) / Roche
Review, Journal: The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. (Pubmed Central) - Aug 1, 2020 The discovery of newer HER2-targeted therapies, such as Pertuzumab (Perjeta), has further added to the armamentarium of treating HER2-positive breast cancers. This review highlights recent advancements in the treatment of HER2-positive diseases, including the newer HER2-targeted therapies and immunotherapies in clinical trials, which have paved (and will further update) the way for clinical practice, and become part of the standard of care in the neoadjuvant, adjuvant or metastatic setting.
- |||||||||| Review, Journal: HER2-positive advanced breast cancer treatment in 2020. (Pubmed Central) - Jul 30, 2020
Other agents - including other antibody drug conjugates and bispecific antibodies as well as combinations - will lead to further changes in coming years. Additionally, should the numerous putative biomarkers thus identified ever come into use at the clinic, choice of treatment and response evaluation may be substantially changed.
- |||||||||| paclitaxel / Generic mfg., trastuzumab biosimilar / Hetero
Journal: Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service. (Pubmed Central) - Jul 29, 2020 Additionally, should the numerous putative biomarkers thus identified ever come into use at the clinic, choice of treatment and response evaluation may be substantially changed. Through the use data of the different formulations available for trastuzumab and taking into account the prescriptive appropriateness (and patient preferences), it has been possible to identify a SSR scenario of economic convenience due to the greater use of the biosimilar.
|